📰 Eisuke Eguchi News
Page 2 - Eisuke Eguchi News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Eisuke Eguchi. Real-time updates on events, politics, business and more.
April 20, 2022
A Japanese megabank is among the organizations impacted by Russia’s refusal to return hundreds of foreign-owned aircraft in reprisal for sanctions imposed over the countrys invasion of Ukraine.
April 20, 2022
The yen continued to fall in value against the U.S. dollar on April 20, and market players said there are no signs of anything on the horizon that can prop up the Japanese currency.
April 1, 2022
Traditional “nyusha-shiki” welcoming ceremonies boasting big crowds have come back in fashion, as major companies revived their standard, pre-pandemic pomp to greet fresh recruits in-person this year.
February 16, 2022
Saddled with debts to the tune of 1 trillion yen ($8.69 billion), leading auto parts manufacturer Marelli Holdings Co. has turned to major banks and other companies for funds to help turn its affairs around, informed sources said.
January 18, 2022
Mizuho Financial Group Inc. announced a new lineup of top executives as well as measures to restore public confidence after it was reprimanded by the nation’s financial regulator for a series of computer system failures over the past year that deeply tarnished the company’s credibility.
November 27, 2021
The Mizuho Financial Group Inc. and Mizuho Bank Ltd. announced Nov. 26 that their three top executives would resign following a devastating Financial Services Agency investigation that faulted management for eight computer glitches at the megabank this year.
January 6, 2021
Equipment to produce a vaccine is installed at Unigen’s factory in Ikeda, Gifu Prefecture, in December. (Sho Ito) Japanese drug companies are moving at an “unprecedented” pace to develop COVID-19 vaccines, but their foreign rivals have already won the race. Although the government has committed hundreds of billions of yen for a game-changing medicine in the novel coronavirus pandemic, the domestic industry is just not set up for speedy vaccine development, and such projects have long been...